Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HE-33
- Development stage
- Preclinical
- Lead developer
- Immune Modulation
- Modality
- Small Molecules
01
Overview
HE-33 is a small molecule cyclic-AMP (cAMP) derivative developed by Immune Modulation, Inc. (IMI Pharma) for the treatment of autoimmune and inflammatory disorders. It functions by modulating the cyclic-AMP signaling pathway, which is a critical regulator of immune cell activity and cytokine production. By influencing this pathway, HE-33 aims to exert immunomodulatory effects that could be beneficial in managing complex immune-mediated conditions. Currently in the preclinical stage, the drug is being investigated for its potential therapeutic efficacy in Systemic Lupus Erythematosus (SLE) and Graft-Versus-Host Disease (GvHD).
Beyond the preview
Go deeper on HE-33.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HE-33.